Assessment of Histologic Prognostic Factors in Peritoneal Malignant Mesothelioma

• Conditions: Peritoneal Malignant Mesothelioma
• Interventions: Other: No intervention

• Registration Number: NCT05193006
• Lead Sponsor: Hospices Civils de Lyon

Brief Summary

Malignant peritoneal mesothelioma is a rare neoplasm. The most common type, the epithelioid type, has been further divided into histological patterns of tubulo-papillary, acinar, adenomatoid, micropapillary, or solid. Its prognosis is improved by the use of a locoregional treatment combining extensive cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), which increases survival up to 50 months. Histology is one of the most important prognostic variable that, forms the basis for treatment decisions. However, the prognostic of the epithelioid type varies greatly due to its tumor heterogeneity. It is therefore necessary to find prognostic factors of malignant epithelioid peritoneal mesothelioma in order to better define the therapeutic strategy. Among histological factors, solid growth, tumor necrosis, nuclear atypia, and mitotic count were found to be independent prognostic factors in epithelioid malignant pleural mesothelioma. However, in epithelioid malignant peritoneal mesothelioma (EMPM), these factors were studied in small and heterogeneous series in terms of histological growth and definitions used for histological factors. The present large study was conducted to investigate the prognostic impact of several histologic factors in EMPM. Their prognosis impacts were assessed using overall survival (OS) and progression-free survival (PFS) in EMPM.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Status Verified: 2021-12
• Study Start: 2021-12-28
• Study First Submitted: 2021-12-31
• Study First Submitted QC: 2021-12-31
• Last Update Submitted: 2021-12-31
• Study First Posted: 2022-01-14
• Last Update Posted: 2022-01-14
• Primary Completion: 2022-07-15
• Study Completion: 2023-01-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

• • peritoneal malignant mesothelioma

Read More

Exclusion Criteria

• opposition to reuse personnal data

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
peritoneal malignant mesothelioma of grade 1	No intervention	peritoneal malignant mesothelioma of grade 1
peritoneal malignant mesothelioma of grade 3	No intervention	peritoneal malignant mesothelioma of grade 3
peritoneal malignant mesothelioma of grade 2	No intervention	peritoneal malignant mesothelioma of grade 2

Primary Outcome Measures

Name	Time	Method
Assessment of pronostic impact of nuclear grade in comparison with combined grade in peritoneal malignant mesothelioma	3 months to 4 years	Assessment by the review of pathologists

Trial Locations

Locations (6)

University Hospital of Lyon; 🇫🇷 Pierre-Bénite, France

Institut f. Pathologie und Neuropathologie; 🇩🇪 Tübingen, Germany

UZ Gent; 🇧🇪 Gent, Belgium

Zydus Hospitals; 🇮🇳 Ahmedabad, India

The Norwegian Radium Hospital; 🇳🇴 Oslo, Norway

Fundação Champalimaud; 🇵🇹 Lisboa, Portugal